Machine-learning-assisted target prioritization and experimental validation of the neoeriocitrin–mTOR axis in impaired osteogenic differentiation
Abstract
Neoeriocitrin (NEO) is a citrus-derived flavonoid with potential osteoprotective activity, but its pharmacological targets and mechanisms in impaired osteogenic differentiation remain unclear. Osteoporosis-related differentially expressed genes were intersected with predicted NEO targets, and least absolute shrinkage and selection operator regression, random forest, and support vector machine analyses consistently prioritized MTOR for mechanistic investigation. Molecular docking predicted a favorable binding pose of NEO at the 12-kDa FK506-binding protein (FKBP12)–mTOR FKBP12–rapamycin-binding (FRB) interface, while the cellular thermal shift assay (CETSA) demonstrated increased cellular thermal stability of mTOR following NEO treatment, supporting an mTOR-associated intracellular effect. In dexamethasone-treated bone marrow mesenchymal stem cells, NEO dose-dependently restored alkaline phosphatase activity, mineralized nodule formation, and the expression of runt-related transcription factor 2 (RUNX2), osteopontin (OPN), and alkaline phosphatase (ALP). NEO also enhanced autophagic flux, increased the microtubule-associated protein 1 light chain 3 beta (LC3B)-II/LC3B-I ratio, reduced p62 expression, and suppressed dexamethasone-induced phosphorylation of mechanistic target of rapamycin (mTOR) and ribosomal protein S6 kinase 1 (S6K1). Pharmacological inhibition of autophagy with 3-methyladenine (3-MA) and mTOR overexpression both attenuated the pro-osteogenic effects of NEO. Collectively, these findings support an mTORC1-associated S6K1 signaling mechanism linking NEO treatment to autophagy regulation and osteogenic differentiation. NEO may therefore represent a candidate natural compound for further preclinical investigation in osteoporosis-related bone loss.
Related
- BIRC3 facilitates osteogenic differentiation of bone marrow mesenchymal stem cells via NGFR/β-catenin signalling axis
- A stratified cell sheet platform coordinating dual osteogenic and chondrogenic differentiation for osteochondral tissue engineering.
- High-Density Culture and Lipopolysaccharide Cooperatively Activate TAK1–MAPK Signaling to Promote Osteogenic Differentiation in Human Dental Pulp Stem Cells
- ITGBL1 inhibits obesity and osteoporosis by maintaining adipogenic and osteogenic differentiation balance via the NEDD4–PPARγ–RUNX2 axis
- Fate-mapping infiltrating monocytes following experimental myocardial infarction reveals differentiation trajectories in the infarcted heart
BibTeX
@article{wang2026machinelearningassisted,
title = {{Machine-learning-assisted target prioritization and experimental validation of the neoeriocitrin–mTOR axis in impaired osteogenic differentiation}},
author = {Yuhao Wang and Jianguang Luo},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1955945},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1955945},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Machine-learning-assisted target prioritization and experimental validation of the neoeriocitrin–mTOR axis in impaired osteogenic differentiation
AU - Yuhao Wang
AU - Jianguang Luo
PY - 2026
DA - 2026/10/30
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1955945
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1955945
AB - Neoeriocitrin (NEO) is a citrus-derived flavonoid with potential osteoprotective activity, but its pharmacological targets and mechanisms in impaired osteogenic differentiation remain unclear. Osteoporosis-related differentially expressed genes were intersected with predicted NEO targets, and least absolute shrinkage and selection operator regression, random forest, and support vector machine analyses consistently prioritized MTOR for mechanistic investigation. Molecular docking predicted a favorable binding pose of NEO at the 12-kDa FK506-binding protein (FKBP12)–mTOR FKBP12–rapamycin-binding (FRB) interface, while the cellular thermal shift assay (CETSA) demonstrated increased cellular thermal stability of mTOR following NEO treatment, supporting an mTOR-associated intracellular effect. In dexamethasone-treated bone marrow mesenchymal stem cells, NEO dose-dependently restored alkaline phosphatase activity, mineralized nodule formation, and the expression of runt-related transcription factor 2 (RUNX2), osteopontin (OPN), and alkaline phosphatase (ALP). NEO also enhanced autophagic flux, increased the microtubule-associated protein 1 light chain 3 beta (LC3B)-II/LC3B-I ratio, reduced p62 expression, and suppressed dexamethasone-induced phosphorylation of mechanistic target of rapamycin (mTOR) and ribosomal protein S6 kinase 1 (S6K1). Pharmacological inhibition of autophagy with 3-methyladenine (3-MA) and mTOR overexpression both attenuated the pro-osteogenic effects of NEO. Collectively, these findings support an mTORC1-associated S6K1 signaling mechanism linking NEO treatment to autophagy regulation and osteogenic differentiation. NEO may therefore represent a candidate natural compound for further preclinical investigation in osteoporosis-related bone loss.
SN - 1663-9812
ER -